[CAS NO. 6202-23-9] Cyclobenzaprine hydrochloride
PRODUCTS SPECIFICATIONS [6202-23-9]
DESCRIPTION [6202-23-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 311.85 |
| Molecular Formula | C20H22ClN |
| SMILES | CN(C)CC/C=C1C2=CC=CC=C2C=CC3=CC=CC=C\13.Cl |
Summary
Cyclobenzaprine hydrochloride (MK130 hydrochloride) is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Target: 5-HT Receptor 2A Cyclobenzaprine hydrochloride is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine hydrochloride was thought to be an alpha 2-adrenoceptor agonist that reduced muscle tone by decreasing the activity of descending noradrenergic neurons. Cyclobenzaprine hydrochloride reduced the monosynaptic reflex amplitude dose dependently and this effect was not inhibited by the alpha 2-adrenoceptor antagonists idazoxan and yohimbine. Cyclobenzaprine-induced monosynaptic reflex depression was not attenuated by noradrenergic neuronal lesions produced by 6-hydroxydopamine. Cyclobenzaprine hydrochloride is a 5-HT2 receptor antagonist and that its muscle relaxant effect is due to inhibition of serotonergic, not noradrenergic, descending systems in the spinal cord [1]. The inhibitory effects of Cyclobenzaprine hydrochloride on mono- and polysynaptic reflex potentials are due to the inhibition of descending serotonergic systems through 5-HT(2) receptors in the spinal cord [2].
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00246389 | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. |
Pain|Spasm
|
Phase 4 | |
| NCT03353922 | Neurana Pharmaceuticals, Inc.|Cognitive Research Corporation |
Driving Impaired
|
July 31, 2017 | Phase 1 |
| NCT01028014 | University of Alabama at Birmingham|Astellas Pharma Inc |
Urethral Sphincter Activity
|
April 2010 | Not Applicable |
| NCT01689259 | Tonix Pharmaceuticals, Inc. |
Healthy Adults
|
September 2012 | Phase 1 |
| NCT03127592 | Apsen Farmaceutica S.A. |
Pain, Acute
|
October 5, 2020 | Phase 3 |
| NCT02642861 | Tanta University |
Liver Cirrhosis
|
October 2018 | Phase 3 |
| NCT02974166 | Instituto Brasileiro de Osteopatia |
Temporomandibular Disorder
|
March 2012 | Not Applicable |
| NCT04407377 | Neurana Pharmaceuticals, Inc. |
Healthy
|
June 20, 2020 | Phase 1 |
| NCT01587274 | Montefiore Medical Center |
Acute Low Back Pain
|
April 2012 | Phase 4 |
| NCT00790270 | Stony Brook University |
Cervical Strain
|
January 2003 | Phase 2 |
| NCT00778037 | Ranbaxy Laboratories Limited|Ranbaxy Inc. |
Healthy
|
September 2006 | Not Applicable |
| NCT01634412 | Tonix Pharmaceuticals, Inc. |
Healthy Adults
|
June 2012 | Phase 1 |
| NCT01081990 | NorthShore University HealthSystem |
Postoperative Pain
|
April 2010 | Not Applicable |
| NCT00913419 | Sandoz |
Depression
|
November 1988 | Phase 1 |
| NCT01889173 | Tonix Pharmaceuticals, Inc. |
Healthy Adults
|
June 2013 | Phase 1 |
| NCT03511118 | Duke University|The Emmes Company, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Lactating Women on Select DOI|Breastfed Infants of Mothers on Select DOI
|
October 4, 2018 | |
| NCT01587508 | Eurofarma Laboratorios S.A. |
Acute Lumbago
|
May 2013 | Phase 3 |
| NCT02403687 | Express Specialty Pharmacy |
Arthritis|Tendonitis|Gout|Radiculopathy|Muscle Spasms|Synovitis|Migraine|Headache
|
June 2015 | |
| NCT02862977 | EMS |
Musculoskeletal Pain
|
November 10, 2017 | Phase 3 |
| NCT02814565 | Takeda |
Neck Pain|Back Pain|Spasm
|
October 12, 2016 | Phase 3 |
| NCT04771741 | Prisma Health-Midlands |
Bunion of Unspecified Foot|Bunionette of Unspecified Foot|Hammertoe|Ankle Fractures|Achilles Tendon Surgery
|
December 1, 2020 | |
| NCT01151787 | Kennedy Medical Group|Teva Pharmaceuticals USA |
Chronic Migraine
|
July 2010 | Phase 3 |
| NCT01041495 | State University of New York - Upstate Medical University|Cephalon |
Fibromyalgia|Pain|Sleep|Fatigue
|
June 2009 | Phase 4 |
| NCT03025113 | EMS |
Musculoskeletal Pain
|
March 8, 2018 | Phase 3 |
| NCT01921296 | Lynn Henry|Damon Runyon Cancer Research Foundation|University of Michigan Rogel Cancer Center |
Sleep Initiation and Maintenance Disorders|Pain
|
August 2013 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : ≥ 100 mg/mL ( 320.67 mM )
DMSO : 50 mg/mL ( 160.33 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.2067 mL | 16.0333 mL | 32.0667 mL |
| 5 mM | 0.6413 mL | 3.2067 mL | 6.4133 mL |
| 10 mM | 0.3207 mL | 1.6033 mL | 3.2067 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 110 mg/mL (352.73 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.02 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.02 mM); Clear solution
References
- [1] Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311(1): p. 29-35.
- [2] Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol, 2003. 458(1-2): p. 91-9.
Synonyms